Shares sold at $10.00 each; Citigroup, Jefferies, Guggenheim assisted
By Devika Patel
Knoxville, Tenn., May 31 – Merus BV said the underwriters for its initial public offering of stock opted to exercise the deal’s $8.25 million greenshoe in part, lifting total proceeds of the offering to $61.4 million. The deal was announced Oct. 19 and priced for $55 million with the greenshoe on May 19.
The company sold 6,139,926 common shares at $10.00 per share. Of the shares, 639,926 were part of the partially exercised greenshoe.
Citigroup Global Markets Inc. and Jefferies LLC were the joint bookrunning managers. Guggenheim Securities, LLC was a joint lead manager.
Proceeds will be used for clinical development, research and development activities and for working capital and other general corporate purposes.
The immuno-oncology company is based in Utrecht, the Netherlands.
| Issuer: | Merus BV
|
| Issue: | Common stock
|
| Amount: | $61,399,260, including $6,399,260 greenshoe of 639,926 shares
|
| Shares: | 6,139,926
|
| Price: | $10.00
|
| Warrants: | No
|
| Bookrunners: | Citigroup Global Markets Inc. and Jefferies LLC
|
| Lead manager: | Guggenheim Securities, LLC
|
| Co-manager: | Wedbush PacGrow
|
| Announcement date: | Oct. 19, 2015
|
| Pricing date: | May 19
|
| Settlement date: | May 31
|
| Stock symbol: | Nasdaq: MRUS
|
© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere.
For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.
